Furthermore, in adjusted model III (adjusted sex, age, duration of diabetes, hypertension, HbA1c, total cholesterol, BMI, eGFR, direct bilirubin, PRP degree, and anti-VEGF therapy), the results were consistent (β = −11.95, 95% CI: −22.08, −1.82; p = 0.0218; β = −14.96, 95% CI: −28.02, −1.90; p = 0.0259, respectively). This evidence concerns the gene VEGFA and diabetes mellitus.